Chemotherapy is widely known to damage the intestinal lining as a common side effect. However, this injury does not remain confined to the gut. Instead, it reshapes nutrient availability for intestinal bacteria, forcing the gut microbiota to adapt and triggering broader systemic effects.
Study Links Chemotherapy to Microbiota-Driven Metabolic Changes
In a study published in Nature Communications, researchers report that chemotherapy-induced injury to the intestinal lining alters nutrient availability for gut bacteria. As a result, the microbiota undergoes significant restructuring and increases the production of indole-3-propionic acid (IPA), a microbial metabolite derived from the amino acid tryptophan.
IPA Acts as a Systemic Immune Signal
Rather than acting locally within the gut, IPA functions as a systemic messenger. After entering the bloodstream, it travels from the intestine to the bone marrow, where it reshapes immune cell production.
Specifically, elevated IPA levels reprogram myelopoiesis by reducing the generation of immunosuppressive monocytes. These monocytes typically promote immune evasion and support metastatic tumour growth. By limiting their production, IPA shifts the immune system toward a more anti-metastatic state.
Researchers Highlight an Unexpected Immune Cascade
“We were surprised by how a side effect often considered collateral damage of chemotherapy can trigger such a structured systemic response,” said Ludivine Bersier, first author of the study. “By reshaping the gut microbiota, chemotherapy initiates a cascade of events that rewires immunity and makes the body less permissive to metastasis.”
Enhanced Anti-Tumour Immunity and Metastasis Resistance
This immune reprogramming strengthens T-cell activity and remodels immune interactions within metastatic niches, particularly in the liver. Consequently, preclinical models show the development of a metastasis-refractory state, limiting the ability of cancer cells to establish secondary tumours.
Patient Data Support Clinical Relevance
Importantly, the experimental findings align with clinical observations. In collaboration with Dr. Thibaud Koessler from Geneva University Hospitals (HUG), researchers analysed patient data from individuals with colorectal cancer.
As reported by medicalxpress, the analysis revealed that patients with higher circulating IPA levels following chemotherapy also exhibited reduced monocyte levels. This immune profile is associated with improved survival outcomes, reinforcing the translational relevance of the findings.
A Newly Identified Gut–Bone Marrow–Liver Axis
“This work demonstrates that the effects of chemotherapy extend far beyond the tumour itself,” said Tatiana Petrova, corresponding author of the study. “By uncovering a functional axis linking the gut, bone marrow, and metastatic sites, we highlight systemic mechanisms that could be harnessed to durably limit metastatic progression.”
New Opportunities for Microbiota-Based Therapies
Together, these findings reveal a previously underappreciated gut–bone marrow–liver metastasis axis through which chemotherapy can exert lasting systemic effects. Moreover, the study opens new avenues for using microbiota-derived metabolites, such as IPA, as adjuvant strategies to strengthen anti-cancer immunity and reduce metastatic spread.